uniQure N.V. (NASDAQ:QURE) Receives $64.42 Average Price Target from Analysts

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned an average recommendation of “Moderate Buy” from the fourteen research firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $64.4167.

A number of research firms have recently commented on QURE. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Sunday. Weiss Ratings reissued a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, October 8th. Leerink Partners cut their target price on shares of uniQure from $68.00 to $60.00 and set an “outperform” rating on the stock in a research report on Monday, November 10th. William Blair reaffirmed a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Finally, HC Wainwright dropped their price target on uniQure from $110.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, November 4th.

uniQure Trading Down 4.7%

Shares of QURE stock opened at $25.32 on Friday. uniQure has a fifty-two week low of $6.11 and a fifty-two week high of $71.50. The stock’s fifty day moving average price is $46.27 and its two-hundred day moving average price is $26.08. The company has a debt-to-equity ratio of 1.53, a quick ratio of 9.98 and a current ratio of 9.98. The company has a market cap of $1.58 billion, a PE ratio of -6.46 and a beta of 0.59.

uniQure (NASDAQ:QURE) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $4.46 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. Equities analysts predict that uniQure will post -3.75 EPS for the current fiscal year.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, September 26th. The stock was sold at an average price of $55.00, for a total value of $825,000.00. Following the completion of the transaction, the chief financial officer owned 217,730 shares of the company’s stock, valued at $11,975,150. This represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Matthew C. Kapusta sold 226,316 shares of uniQure stock in a transaction that occurred on Wednesday, September 24th. The stock was sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the sale, the chief executive officer owned 651,454 shares in the company, valued at approximately $27,009,282.84. This represents a 25.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 314,560 shares of company stock worth $12,362,568 in the last 90 days. 4.79% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On uniQure

Several large investors have recently modified their holdings of QURE. Private Trust Co. NA acquired a new position in shares of uniQure during the third quarter worth $28,000. Jones Financial Companies Lllp raised its position in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. CIBC Private Wealth Group LLC acquired a new position in uniQure during the 3rd quarter worth about $50,000. Tower Research Capital LLC TRC lifted its holdings in uniQure by 358.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after buying an additional 5,538 shares during the period. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of uniQure in the 2nd quarter valued at about $117,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.